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Rat diaphragm contractility and histopathoiogy 
are affected differently by low dose treatment 
with methylprednisolone and deflazacort
P.N.R. Dekhuijzen, G. Gayan-Ramirez, A. Bisschop, V. de Bock,
R. Dom, R. Bouillon, M. Decramer
Rat diaphragm contractility and histopathoiogy are affected differently by low dose treat- 
meni with methylprednisolone and deflazacort. P.N.R. Dekhuijzen, G. Gayan-Ramirez, 
A. Bisschop, V. de Bock, R. Dom, R. Bouillon, M. Decramer. ©ERS Journals Ltd 1995. 
ABSTRACT: The extent to which treatment with low doses of the nonfluorinated 
steroid methylprednisolone affects diaphragm contractility and morphology is 
unknown. In the present study, we compared the effects of equipotent doses of 
methylprednisolone and deflazacort, an oxazoline derivate of prednisolone with 
less systemic si de-effects on bone structure and carbohydrate metabolism.
Twenty six male adult rats were randomized to receive daily saline (control), 
methylprednisolone 0.4 mg»kg-1 or deflazacort 0.5 mg-kg1 i.m. Contractile proper­
ties and histopathoiogy were measured after a 6 week treatment period.
During treatment» body weight increased in control and methylprednisolone- 
treated animals, but decreased by 4.2±1.1% (meanisn) in the deflazacort group. 
Similarly, diaphragm mass in the deflazacort group was decreased compared to 
control and methylprednisolone groups. Twitch tension and twitch characteristics 
of isolated diaphragm bundles were similar in the three groups. Maximal tetanic 
tension was decreased in the deflazacort group. The force-frequency curve of the 
deflazacort bundles shifted downwards compared to control. Fatigue occurring 
during this protocol was greatest in the methylprednisolone- and deflazacort-treat- 
ed animals. Microscopic examination revealed no gross abnormalities in the three 
groups. Histochemical analysis after staining for myosin adenosine triphosphatase 
(ATP-ase) showed that in the deflazacort group cross-sectional area of type I, Ila 
and Üb fibres were decreased.
We conclude that low doses of methylprednisolone caused subtle and negligible 
changes in rat diaphragm contractile properties without affecting Fibre dimensions, 
while deflazacort at an equipotent dose induced generalized fibre atrophy and changes 
in diaphragm contractility.
Eur Respir J., J995, 8, 824-837 .
Respiratory Muscle Research Unit, Lab­
oratory of Pneumology and Respiratory 
Division, and Depts of Neuropathology 
and Endocrinology, University Hospital, 
Katholieke Universiteit Leuven, Leuven, 
Belgium.
Correspondence: M. Decramer 
Respiratory Division 
University Hospital Gasthuisberg 
Herestraat 49 
3000 Leuven 
Belgium
Keywords: Corticosteroids
diaphragm
myopathy
respiratory mechanisms 
respiratory muscles .
Received; July 4 1994
Accepted after revision February 5 1995
Supported by grants from the "Dutch As­
thma Foundation" and "Fonds voor Gen­
eeskundig Wetenschappelijk Onderzoek",
Recent animal studies have demonstrated that adminis­
tration of corticosteroids affects diaphragm structure and 
function [1-6]. Fluorinated steroids (e.g. triamcinolone 
0.5-3 mg'kg1 Lm. and dexamethasone 1-4 mg-kg-1 i.m. 
administered during 1-7 weeks) caused severe loss of 
body weight and muscle mass up to 40%. This was 
accompanied by type l i b  fibre atrophy in the diaphragm 
as well as in peripheral skeletal muscles [1-5]. These mor­
phological ¿Iterations were reflected in changes in the 
physiological properties of isolated diaphragm bundles, 
which showed a shift towards the contractile profile of 
slow muscle. In contrast, the nonfluorinated steroid pred­
nisolone, administered in a dose of 5 mg'kg4 i.m. daily 
during 4 weeks, did not cause loss of body mass [4]. 
Histological examination revealed myogenic changes in 
the diaphragm, including greater than normal variation 
of the diameter of all fibre types, scattered necrotic fibres, 
excess nuclei, and an increased amount of connective
tissue, but without fibre atrophy. In line with these 
alterations, an increased tendency towards fatigue was 
observed when examining the contractile characteris­
tics of the diaphragm bundles.
In the above mentioned studies, moderate to high doses 
of corticosteroids were administered. It remains unclear 
whether lower doses may cause alterations in animal 
diaphragm. In patients with chronic obstructive pulmo­
nary disease (COPD) there is evidence to suggest that 
treatment with low doses of methylprednisolone (MP) 
affects respiratory and peripheral muscle force [7].
The aim of the present study, therefore, was to investi­
gate whether in rats contractile properties of the dia­
phragm (DIA) and morphological characteristics of 
DIA and gastrocnemius muscle (GA) were affected by 
treatment with a low dose (0.4 mg-kg'1 i.m. daily) of MP, 
theoretically comparable to doses commonly used for 
therapeutic purposes in humans. In addition, we studied
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the effects of an equipotent dose of deflazacort (DF), 
0.5 mg-kg-1 Lm. daily, an oxazoline derivate of predni­
solone with similar anti-inflammatory and immunosup­
pressive activity [8], but less side-effects on bone structure 
and carbohydrate metabolism compared to prednisolone
[9, 10].
Methods
Study design, animals and treatment
Twenty six adult male Wistar rats, aged 18 weeks, 
weighing 350-400 g, were randomized into one of three 
treatment groups: 1) control (C), (n=10), saline 0.05 ml 
daily Lm.\ 2) methylprednisolone (MP), (n=10), 0.4 
mg-kg-1 daily Lm.\ and 3) deflazacort (DF), (n=6), 0.5 
mg’kg'1 daily Lm.
The dosages of MP and DF were chosen in order to 
administer an equivalent anti-inflammatory dose to the 
animals. During 6 weeks, the animals were injected daily 
in the left hind limb. They were fed ad libitum. All 
animals were weighed thrice weekly. After the treat­
ment period, contractile properties of DIA and histo­
logical and histochemical characteristics of DIA and 
G A were examined.
Contractile properties
Twenty four hours after the last injection, rats were 
anaesthetized with sodium pentobarbital (Nembutal), 
60 mg-kg-1 Lp. Animals were tracheotomized and a tra­
cheal cannula (polyethylene tubing PE-200) was inserted. 
They were mechanically ventilated with an 0 2 enriched 
gas mixture (Harvard pump respirator, South Natick,
Ma, USA).
The diaphragm was quickly removed through a lap­
arotomy, and immediately immersed in a cooled, oxy­
genated Krebs solution containing (in mM*L_I): NaCI 
137, KC1 4, CaCl2 2, MgCl2 1, KH2P04 1, NaHC03 12,
glucose 6.5. To avoid regional differences in cross- 
sectional area or fibre type proportions as much as pos­
sible, two small rectangular bundles from the middle 
part of the lateral costal region were obtained by dis­
section parallel to the long axis of the fibres. Silk su­
tures were tied to both ends of the bundle to serve as 
anchoring points.
Each bundle was then placed within the external 
chamber of a jacketed tissue bath containing Krebs 
solution, maintained at 37°C and perfused with a 95%
0 2 and 5% C02 mixture. One end of the bundle was tied 
to a rigid support, while the other was fastened to an 
isometric force transducer mounted to a micrometer. 
The muscle was placed in between two large platinum 
stimulating electrodes.
The bundles were placed at their optimal length (Lo), 
defined as the length at which peak twitch force was 
obtained. This was followed by a 15 min thermoequi­
libration period. Stimulations were delivered through a 
Harvard 50-5016 stimulator (Edenbridge, Kent, UK), 
connected in series to a power amplifier from power 
one model HS24-4.8. Stimuli were applied with a pulse
duration of 0.2 ms and a train duration of 250 ms. 
Maximum twitch force was achieved at ±34 V. The volt­
age was then increased by 20% to ensure supramaximal 
stimulation. This voltage was subsequently used during all 
stimulations. Isometric force was measured by means of a 
Maywood force transducer (Maywood Ltd, Hampshire, 
UK). The signal was amplified and recorded on computer 
via analogue to digital conversion (DT2801-A) using Lab- 
dat software (Labdat/Anadat, RHT-InfoDat, Montreal, 
Canada). Signal analysis was performed with Anadat.
The following measurements were carried out: 1) Twitch 
characteristics - two twitches were recorded at Lo to de­
termine maximal twitch tension (Pt), time to peak tension 
(TPT) and half-relaxation time (1/2RT). Average values 
were used for further analysis; 2) Maximal tetanic ten­
sion (Po): bundles were stimulated twice tetanically at 
160 Hz, during 250 ms, in order to obtain a clear plateau 
in force generation [11, 12]; 3) Force-frequency curve - 
bundles were stimulated at the following frequencies: 25, 
160, 50, 160, 80, 160, 120 and 160 Hz. Each stimulus 
was separated by a 2 min interval; and 4) Fatigue prop­
erties: fatigability was assessed in two different ways. 
Firstly, force output at 160 Hz after each stimulus fre­
quency during the force-frequency curve was measured. 
Secondly, bundles were fatigued by means of 330 ms 
stimulations repeated every 2 s at 25 Hz during 5 min 
(modified after B u r k e  et ai [13]).
After these measurements, each muscle bundle was 
removed from the bath and its length, thickness and 
width was measured at Lo. The bundle was blotted dry 
and weighed. Cross-sectional area (CS A) was calculated by 
dividing weight by specific density (1.056) and muscle 
length. Forces were expressed per unit CSA [3, 14]. 
Twitch-to-tetanus ratio (Pt/Po) was calculated for each 
muscle bundle.
Finally, the remaining diaphragmatic tissue was trim­
med, blotted and weighed. Parasternal muscles (including 
sternum and chondral parts of the ribs), the right medial 
scalene muscle, and the gastrocnemius and soleus mus­
cles from the right hind limb were dissected, trimmed, 
blotted and weighed, as well as the two adrenal glands.
Histological and histochemical procedures
Muscle strips obtained from the costal region of the 
diaphragm and from the mid-belly of the GA of the right 
hind limb were prepared for histopathological examin­
ation, Muscle samples were put into "tissue glue" (Tissue- 
Tek, Elkhard, IN, USA) on a cork holder, with the muscle 
fibres orientated perpendicularly to the surface of the 
cork. Proper orientation of the bundles was controlled 
by using magnifying glasses. Subsequently, these speci­
mens were quickly frozen in isopentane cooled with 
liquid N2. Serial cross-sections were cut at 10 \im thick­
ness with a cryostat kept at -20°C, parallel to the cork. 
Sections of each DIA and GA were taken for routine 
haematoxylin and eosin staining.
The other serial sections were stained for myofibril­
lar adenosine triphosphatase (ATPase) after alkaline (pH 
9.3) and acid (pH 4.5) preincubation. Muscle fibres were 
classified as type I (slow-twitch), type Ha (fast-twitch
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oxidative), or type lib (fast-twitch glycolytic) fibres [15]. 
Slides preincubated at pH 4.5 offered the best separa­
tion of different fibre types, and were subsequently used 
for further analysis.
Morphometrie examination was carried out with a 
Leitz microscope (Wetzlar, Germany) at x25 magnifi­
cation, connected to a digitizing board (Numonics 2207; 
Montgomeryville, PA, USA)» Areas in which fibre ori­
entation was not transverse to the long axis of the fibre 
were not analysed. Boundaries of individual muscle 
fibres were delineated, and fibre CSA was determined 
from the number of pixels within the outlined fibre. At 
least 150 fibres of each DIA and deep (red) part of the 
GA were used to calculate mean CSA of all fibre types.
500 -
Data analysis
Two diaphragm bundles were obtained from each ani­
mal. Since variation between animals was as large as 
within animals, all bundles were used for statistical an­
alysis as independent cases. Data from the different treat­
ment groups were compared, using two-way analysis of 
variance. Differences between means were assessed 
using Duncan’s multiple range test. A chi-squared likeli­
hood ratio test was used to detect differences in the dis­
tribution of maximal tetanic tensions between the three 
treatment groups. Statistical significance was set at a 
value of p less than 0.05. All analyses were performed 
using the statistical Package for the Social Sciences 
(SPSS)/PC+ package [16]. Means±SD are represented in 
text, tables and figures, unless otherwise specified.
Results
Body, muscle and adrenal weight
Body weight at the start of the study was not differ­
ent between the three groups (fig. 1). During the treatment 
period, weight increased by 10.9±1.7% in C, and by 
6.6±1.4% in MP-treated animals, whereas it decreased 
by 4.2±1.1% in the DF group (p<0.05 compared to C).
Muscle masses in the DF group were significantly 
reduced compared to C (DIA, scalenus and G A) and MP 
(scalenus and G A) (table 1). No changes occurred in the 
parasternal muscles, probably because the major part of 
the weight consisted of the ribs. In addition, the mass of 
the adrenal glands was decreased compared to C and
Table 1. -  Muscle and adrenal masses
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Fig. 1. -  Body weight vs time during the 6 week treatment period. 
; control;— O — : methylprednisolone; —■ — : deflazacort;
------ : pooled s d . *: deflazacort compared to control; p<0.05 for all
data points» except for time 0.
MP. The ratio of DIA mass to total body weight was sim­
ilar among the three groups (C 0.16±0.03%, MP: 0.15±
0.02%, DF; 0.17±0.02%).
Diaphragmatic contractile properties
Bundle dimensions. Bundle dimensions are shown in 
table 2. The DIA bundles in the DF group tended to be 
smaller, but no significant differences were found com­
pared to the other groups.
Twitch characteristics and maximal tetanic tension. The 
data of the contractile properties of the DIA are sum­
marized in table 3. Pt, TPT, 1/2RT and Pt/Po were simi­
lar in the three groups. Po (expressed both as absolute 
values (kg) and corrected per CSA (kg-cnr2)) was decrea­
sed in the DF group (p<0.05). When the values were 
divided in two classes (Po <2.0 and >2.0 kg-cm*2), more 
bundles in the DF-treated animals generated tetanic ten­
sions below 2.0 kg-cnr2 (37%, compared to 10% in the 
other two groups; x2=8.712, p<0.05).
Force-frequency curve. The response of diaphragm strips 
to increasing stimulus frequencies is shown in figure 2. 
When expressed in absolute values (kg-cm-2), a significant
Treatment Diaphragm
(DIA)
mg
Paras temals 
mg
Scalenus
mg
Gastrocnemius
(GA)
mg
Soleus
mg
Adrenal glands 
mg
Control (C) 663 (67) 3233 (311) 578 (56) 2238 (179) 163 (17) 45 (3)
Methylprednisolone (MP) 626 (40) 3171 (167) 580 (53) 2053 (137)* 165 (12) 42 (6)*
Deflazacort (DF) 597 (39)* 3176 (299) 504 (46)*# 1872 (132)*# 155 (15) 29 (7)*#
Data are presented as mean, and sd in parenthesis. *: p<0.05 compared to control; #: p<0.05 compared to methylprednisolone.
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Table 2. -  Diaphragm bundle dimensions
Treatment Length
mm
Thickness
mm
Width
mm
Weight
mg
Control 21.2 (1.9) 0.51 (0.13) 1.62 (0.20) 28.5 (6.2)
Methyl­
prednisolone
20.3 (2.2) 0.53 (0.12) 1.62 (0.24) 27.1(5.3)
Deflazacort 19.8 (2.5) 0.46 (0.11) 1.60 (0.28) 25.2 (7.1)
Data are presented as mean.
downward shift of the DF bundles at 50, 80 and 120 Hz 
was observed (p<0.05) (fig. 2a). A nonsignificant dec­
rease in force generation was observed in the MP bun­
dles. When expressed as a percentage of the 160 Hz 
stimulations before and after each stimulus frequency, 
no differences were observed among the three groups 
(fig. 2b).
Fatigue properties. In all groups, force generated at 160 
Hz decreased during the force-frequency stimulation pro­
cedure. In the C, M P and DF groups, the values for 
percentage decrease relative to initial Po were 8.0±1.9, 
15.4 ±2.6, and 19.6±5.8 (mean±sE), respectively. This
decrease in generated force in the M P and DF groups 
was significantly higher than in C (p<0.05.)
During the low-frequency fatigue run, stress generation 
in absolute values (kg-cnr2) was similar in all groups (fig. 
3a). When expressed as a percentage of initial stresses, 
this ratio (fatigue/fresh, a dimensionless index) was high­
er in the DF bundles (fig. 3b), (p<0.05).
Histology and histochemistry
Histological examination of haematoxylin and eosin 
stained slides showed a normal muscular pattern of DIA 
and GA in the three groups.
Analysis of ATPase stainings showed that fibre type 
distribution was not changed by the different treatments. 
For groups taken together, the DIA consisted of 40.4± 
5.3% type I fibres, 29.7±6.1% type Ha fibres, and 29.9± 
4.2% type lib fibres. The red (deeper) part of the GA 
consisted of 30.1±4.5% type I fibres, 25.3±5.1% type Ila 
fibres, and 44.6±6.5% type lib fibres. Dimensions of 
the three fibre types in both DLA and G A were similar 
in C and MP groups (fig. 4). Treatment with DF, how­
ever, was accompanied by a decrease of diaphragmatic 
type I, Ila, and lib fibre cross sectional area (p<0.05 
compared to the other groups) (fig. 4a). Similar changes 
were observed in the G A (fig. 4b).
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Fig. 2. -  a) Force-frequency curve of diaphragm bundles, b) Force-frequency curve of diaphragm bundles, expressed as percentage of interspersed
160 Hz stimulations. ■ ■+■■■ ■ : control; —O — : methylprednisolone; : deflazacort;------ : pooled s d ;  *: p<0.05 deflazacort compared to
control.
Table 3. -  Diaphragmatic contractile properties
Treatment Pt
kg-cm'2
TPT
ms
1/2RT
ms
Po
kg
Po 
kg* cm*2
Pt/Po
Control 0.72 (0.19) 19 (2) 24 (2) 0.033 (0.009) 2.57 (0.45) 0.28 (0.04)
Methylprednisolone 0.70 (0.15) 20 (2) 24 (4) 0.031 (0.009) 2.46 (0.33) 0.28 (0.05)
Deflazacort 0.62 (0.16) 19 (2) 25 (2) 0.028 (0.008)* 2.32 (0.45)* 0.27 (0.06)
Data are presented as mean (sd ) . Pt: twitch tension; TPT: time to peak tension; 1/2RT: half-relaxation time; Po: tetanic tension; 
Pt/Po: twitch/tetanic ratio. *: p<0.05 compared to control.
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Discussion
The present study shows that low dose MP adminis­
tered during 6 weeks hardly affects the contractile prop­
erties of the rat diaphragm, if at all. Only subtle changes 
were found, such as slightly increased fatigability during 
high-frequency stimulation and a nonsignificant down­
ward shift of the force-frequency curve. MP did not alter 
diaphragm or gastrocnemius morphology. Treatment with 
DF, however, was associated with more pronounced chan­
ges in the contractile characteristics of the diaphragm. 
These alterations consisted of a decrease in maximal tet­
anic tension, a downward shift of the force-frequency 
curve and decreased maximal tension generation dur­
ing this protocol. In contrast to MP, DF caused mild atro­
phy of all fibre types, both in the diaphragm and in the 
gastrocnemius. In line with these findings, treatment with 
DF was accompanied by slight loss of body and muscle 
mass.
Interpretation of the results
Side-effects, such as changes in bone and carbo­
hydrate metabolism, associated with the use of DF appear 
to be less than with prednisolone [17-20]. Comparisons 
between DF and MP have not been made to our knowl­
edge, nor have animal studies been published regarding 
the effects of DF on respiratory and peripheral skeletal 
muscles.
One early study has been published regarding the ef­
fects of MP on skeletal muscles in dogs [21]. In this 
study, the effects of (among other steroids) prednisolone 
25 mg i.m, and MP 20 mg i.m. daily during 5 weeks were 
compared. Body weight decreased by ±10% in both groups. 
Prednisolone caused mild atrophy (not specified for dif­
ferent fibre types) in the quadriceps muscle, whereas MP 
did not change fibre size. This is in line with the mor­
phological findings in the present study.
The pattem of fibre atrophy associated with DF in the
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present study is clearly different from the selective type 
Hb fibre atrophy caused by fluorinated steroids [1-5]. 
Instead, this pattern of generalized fibre atrophy resem­
bles the changes accompanying loss of body and dia­
phragm mass induced by nutritional depletion [5,22,23], 
In a previous study, we showed that 44% loss of diaphragm 
mass induced by nutritional restriction, was accompanied 
by a decrease in CSA of type I, Ila, and lib fibres of 31, 
35 and 52%, respectively [5]. In comparison, treatment 
with DF in the present study resulted in a loss of diaphragm 
mass of 10%, associated with decreases in CSA of 23, 31 
and 23%, respectively. These changes indicate that diaphragm 
fibre CSA is very sensitive to changes in body mass.
The changes in contractile properties induced by DF, 
however, were different from those induced by nutritional 
depletion. The latter is associated with a shift towards the 
functional profile of a slow muscle with increased half­
relaxation time and an upward shift of the force-frequency 
curve [5]. In contrast, the decrease in maximal tetanic 
tension and the downward shift of the force-frequency 
curve in the DF group suggest that, besides atrophy, DF 
also caused a decrease in force generation (myopathy). 
These findings are similar to those found after treatment 
with prednisolone, 5 mg-kg-1 i.m. daily during 4 weeks
[4]. The increased ratio fatigued/fresh in the DF bundles 
at the end of the fatigue run (fig. 3b) may be due to the 
initial decrease of force during the force-frequency pro­
tocol. This resulted in a lower force at the start of the fatigue 
protocol, but the eventual force generation was similar to 
the other groups.
It might be argued that variation in bundle dimen­
sions may be responsible for the alterations in contrac­
tile properties, by changes in diffusion of substrates and 
oxygen. S e g a l and F a u lk n e r  [24] studied the influence 
of muscle thickness and incubation temperature on the 
contractile properties of rat skeletal muscles. They showed 
that the critical radius for 0 2 diffusion (i.e. the distance 
into a muscle at which 0 2 tension declined to zero) was 
-0.6 mm at 37°C. This is clearly above the radius of the 
bundles in our study, which varied from 0.23 (D F  group) 
to 0.27 mm (MP group). If the reduced dimensions of 
the bundles in the D F group would, nevertheless, alter 
force generation, these bundles would be expected to be 
more resistant to fatigue compared to larger bundles, and 
not less resistant as was observed.
Mechanisms of steroid-induced changes in striated mus­
cle
The mechanism of steroid-induced changes in striated 
muscle is complex and in part unknown. Protein wast­
ing is due to a reduction in protein synthesis and to an 
increase in intracellular proteolysis. Inhibition of protein 
synthesis occurs primarily in type II muscle fibres, mainly 
by affecting the activity of factors involved in peptide 
initiation [25]. Increased muscle cytoplasmatic protease 
activity, associated with steroid treatment, results in 
myofibrillar destruction [26]. Carbohydrate metabolism 
within muscle fibres is also affected by corticosteroids. 
Muscle glycogen content is increased by increased muscle 
glycogen synthetase activity and decreased glycogen
utilization [27]. Mitochondrial alterations in muscles 
affected by steroids have suggested that impaired oxida­
tive respiration may also be an important factor in patho­
genesis [28].
There is no clear explanation for the difference in res­
ponse of striated muscle to different subgroups of glucocorti- 
costeroids, such as fluorinated and nonfluorinated steroids. 
A  difference in binding of triamcinolone, dexamethasone, 
and cortisol to cytoplasmatic proteins may play a role 
[26]. In the case of DF, another mechanism has been 
proposed, associated with its chemical structure. DF is 
characterized by an oxazoline group at C-17, which is 
believed to sterically hinder reactivity of the side chain 
[29]. This results in a reduced lipid solubility compared 
to prednisolone. Therefore, it has been postulated that 
DF is less extractable from serum by cells with a limit­
ed degree of exposure to the circulation, such as osteoblasts, 
accounting for its favourable effects on bonfe metabolism
[8]. Such a mechanism, however, may be expected to pro­
tect organs with an abundant blood supply, such as the 
dia-phragm, less, as suggested by the findings in the pre­
sent study. A ssan d ri et a l  [30] showed that the concen­
tration of deflazacort in striated muscle in rats after oral 
administration of 5 mg-kg'1 deflazacort was low. Data 
on the diaphragm were not presented.
Potential clinical significance o f  steroid-induced alter­
ations
In previous studies, the doses of steroids administered 
were high compared to current use in clinical practice. 
In the present study, MP and DF were administered in 
low doses, comparable with the dose sometimes admin­
istered to patients with asthma or COPD. In these patients, 
diaphragm function is compromized by malnutrition 
[31, 32], hyperinflation [33], disturbances in blood gases 
[34], and cardiac failure [35, 36]. It may be speculated 
that the effects of steroids on already impaired dia­
phragmatic function, as in patients with COPD, might be 
more pronounced.
Z a n o t t i  et a l  [37] showed that respiratory muscle 
strength was similar in patients with COPD treated with 
DF, 15 mg daily for at least four consecutive months, 
compared to COPD patients matched for age and sever­
ity of airflow obstruction. Firm conclusions from this 
study, however, are precluded since it was performed in 
a retrospective and cross-sectional design.
In a recent study, eight out of 21 consecutive patients 
who were admitted to hospital with acute exacerbations 
of COPD or asthma, suffered from generalized muscle 
weakness [7]. In seven of these eight patients the aver­
age daily dose of methylprednisolone during the last 6 
months exceeded 4 mg, whilst this was the case in only 
three of the 13 patients with normal muscle strength. 
Although the therapeutic efficacy of corticosteroids in 
COPD is at least controversial [38], this observation in­
dicates the potential effect of low-dose treatment with 
methylprednisolone on muscle strength.
In summary, this study shows that low dose of MP 
cause only subtle changes in contractile properties of rat 
diaphragm, without alterations in morphology. In con­
trast, more pronounced abnormalities in contractile
830 P.N.R. DEKHUÍJZEN ET A.L.
properties are observed in the DF treated bundles, which 
are accompanied by generalized muscle fibre atrophy in 
both diaphragm and gastrocnemius.
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